TODAY’S PATENT – METHYLSULFONYLMETHANE (MSM) FOR TREATMENT OF DRUG RESISTANT MICROORGANISMS
This patent relates to a method of increasing the susceptibility of methicillin-resistant Staphylococcus aureus (MRSA) to beta-lactam antibiotics, which it typically resists. The invention discloses the use of methylsulfonylmethane (MSM) compositions for the treatment of drug-resistant infectious diseases, particularly MRSA. The patent also provides various compositions that are effective in treating MRSA infections.
The inventors of this technique are Rodney Benjamin, Jeffrey Varelman, and Anthony Keller. It received a patent from USPTO on 10th July 2012 bearing the serial number US8217085B2. The invention involves sensitizing drug-resistant microbes to beta-lactam antibiotics by using MSM. This is a significant breakthrough in the field of medicine as MRSA is a notorious drug-resistant bacterium that has caused many healthcare-associated infections. The use of MSM compositions as described in this patent provides a new approach to treating MRSA infections and other drug-resistant infectious diseases.
The patent is a valuable contribution to the field of medicine and offers new treatment options for drug-resistant infections. The invention has the potential to save many lives and improve healthcare outcomes by providing a more effective way of treating MRSA and other drug-resistant infectious diseases.